Preliminary evaluation of NMN reprotoxicity using human sperm assay
NMN does not impair human sperm motility at concentrations of 50 µM and 100 µM, but 150 µM may have harmful effects.
Where it sits
this study against the rest of the nad+ (nicotinamide adenine dinucleotide) corpusSummary and findings
This study evaluated the effects of nicotinamide mononucleotide (NMN) on human sperm progressive motility using a Human Sperm Assay. Seven normozoospermic semen samples were exposed to NMN at concentrations of 0, 50, 100, or 150 µM over a 24-hour period. The findings indicated that NMN at 50 µM and 100 µM did not impair motility, while 150 µM resulted in a significant reduction in motility.
Abstract
<title>Abstract</title> <p>Human spermatozoa are highly susceptible to oxidative injury owing to their polyunsaturated fatty acid-rich plasma membrane and limited antioxidant defenses. Nicotinamide mononucleotide (NMN), a key NAD⁺ precursor, has gained attention for its roles in cellular energetics and redox balance. However, direct evidence regarding its potential reprotoxic effects on human spermatozoa is lacking. This preliminary Human Sperm Assay (HSA) evaluated the compatibility of NMN with human sperm progressive motility. Seven normozoospermic semen samples were exposed to NMN at 0 (control), 50, 100, or 150 µM. Progressive motility was assessed according to WHO 2021 criteria at baseline and after 0.5, 1, 2, 4, and 24 hours of incubation. NMN at 50 µM and 100 µM did not impair progressive motility relative to untreated controls throughout the 24-hour incubation. In contrast, exposure to 150 µM NMN resulted in a substantial reduction in progressive motility. These preliminary findings suggest that NMN does not exert reprotoxic effects on sperm progressive motility at 50 and 100 µM, whereas 150 µM induces motility impairment. Larger studies with additional sperm function parameters are warranted to confirm the short-term safety of these lower concentrations.</p>
Background
The paper addresses the potential reprotoxicity of NMN (Nicotinamide Mononucleotide) in human sperm, a topic of growing interest due to the increasing use of NAD+ precursors. Prior literature has suggested various biological roles for NAD+ in cellular metabolism, but its effects on human reproductive health remain underexplored. This study is significant as it attempts to fill a gap in understanding the safety profile of NMN in human reproductive biology.
Methods
The study utilized a human sperm assay to assess the reprotoxicity of NMN. Specific details regarding the study design, sample size (n), dose, duration, and outcome measures were not reported in the abstract, which limits the ability to evaluate the robustness of the findings.
Results
Not reported in abstract.
Interpretation
Due to the lack of reported results and specific numeric findings, it is difficult to compare this study's outcomes to existing literature or to assess the clinical significance of any observed effects. The absence of detailed data raises concerns about the reliability of the conclusions drawn from this preliminary evaluation.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Preliminary evaluation with no detailed results.
- Lack of specified doses and outcomes.